✍️ Commentary We have a long-standing, reductionist habit in cardiology of mistaking the laboratory requisition for the patient. When epidemiological associations and Mendelian randomization point to a circulating particle like lipoprotein(a) as a culprit, the pharmaceutical impulse is predictable: design an oligonucleotide to crush the biomarker and assume clinical salvation will follow. But human vascular […]

Read More »